Pharmaron Beijing saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Pharmaron Beijing‘s patent filings and grants. Buy the databook here.
Pharmaron Beijing has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The United States(US) patent Office are among the top ten patent offices where Pharmaron Beijing is filings its patents. Among the top granted patent authorities, Pharmaron Beijing has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Pharmaron Beijing
Hypertrophic cardiomyopathy related patents lead Pharmaron Beijing portfolio followed by myocardial ischemia, and hyperdynamic (warm shock)
Pharmaron Beijing has highest number of patents in hypertrophic cardiomyopathy followed by myocardial ischemia, hyperdynamic (warm shock), neurodegenerative diseases, and sickle cell disease.
For comprehensive analysis of Pharmaron Beijing's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.